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OBJECTIVE — Intensive therapy targeting normal blood glucose increased mortality com-
pared with standard treatment in a randomized clinical trial of 10,251 participants with type 2
diabetes at high-risk for cardiovascular disease (CVD) events. We evaluated whether the pres-
ence of cardiac autonomic neuropathy (CAN) at baseline modiﬁed the effect of intensive com-
pared with standard glycemia treatment on mortality outcomes in the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) trial participants.
RESEARCH DESIGN AND METHODS — CAN was assessed by measures of heart rate
variability (HRV) and QT index (QTI) computed from 10-s resting electrocardiograms in 8,135
ACCORD trial participants with valid measurements (mean age 63.0 years, 40% women). Pre-
speciﬁed CAN deﬁnitions included a composite of the lowest quartile of HRV and highest QTI
quartileinthepresenceorabsenceofperipheralneuropathy.Outcomeswereall-causeandCVD
mortality. Associations between CAN and mortality were evaluated by proportional hazards
analysis, adjusting for treatment group allocation, CVD history, and multiple prespeciﬁed base-
line covariates.
RESULTS — During a mean 3.5 years follow-up, there were 329 deaths from all causes. In
fully adjusted analyses, participants with baseline CAN were 1.55–2.14 times as likely to die as
participants without CAN, depending on the CAN deﬁnition used (P  0.02 for all). The effect
of allocation to the intensive group on all-cause and CVD mortality was similar in participants
with or without CAN at baseline (Pinteraction  0.7).
CONCLUSIONS — Whereas CAN was associated with increased mortality in this high-risk
type2diabetescohort,theseanalysesindicatethatparticipantswithCANatbaselinehadsimilar
mortalityoutcomesfromintensivecomparedwithstandardglycemiatreatmentintheACCORD
cohort.
Diabetes Care 33:1578–1584, 2010
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t has been generally accepted that in-
tensive glycemic control is paramount
for preventing development and pro-
gression of chronic diabetes complica-
tions (1,2). The recently reported
increasedmortalityassociatedwithinten-
sive control of hyperglycemia in the Ac-
tion to Control Cardiovascular Risk in
Diabetes (ACCORD) trial (3) has led to
controversy about implementation of in-
tensive glucose control in patients with
type 2 diabetes.
There was a consistent effect on mor-
tality from the intensive compared with
standard treatment in the prespeciﬁed
subgroup analyses (3). To date no ade-
quateexplanationfortheseﬁndingsofin-
creased mortality with intensive glycemic
control has been identiﬁed.
Cardiac autonomic neuropathy
(CAN), which can be documented by ab-
normal heart rate variability (HRV), oc-
curs commonly in patients with diabetes
and is associated with silent myocardial
ischemia (4) and increased mortality (5).
In addition, peripheral neuropathy is a
prevalent complication of diabetes, and
emerging evidence links excess mortality
in diabetes with the presence of diabetic
peripheral neuropathy (DPN) (6,7).
It is also possible that individuals
with baseline CAN may be more suscep-
tibletomortalityassociatedwithhypogly-
cemia when glycemia therapy is
intensiﬁed because of impaired hormonal
and autonomic responses to subsequent
hypoglycemia (8,9). To further investi-
gate possible contributors to the higher
mortality risk in the intensive glycemia
arm of the ACCORD trial, we examined
whether the presence of CAN at baseline
with or without DPN may have contrib-
uted to this outcome.
RESEARCH DESIGN AND
METHODS— The ACCORD trial de-
signandpatientpopulationhavebeende-
scribed elsewhere (10). In brief, 10,251
subjects with type 2 diabetes at high-risk
for cardiovascular disease (CVD) events
were enrolled in 77 clinical centers across
the U.S. and Canada and randomly as-
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intensive glycemia therapy (INT) target-
ing a A1C level 6% or to receive stan-
dard glycemia therapy (STD) targeting an
A1C level of 7–7.9%. The mean duration
ofthetrialwasexpectedtobe5years.The
INT arm of the study was discontinued
after3.5yearsbecauseofexcessmortal-
ity in the INT group, and all participants
weretransitionedtotheSTDprotocol(3).
The ACCORD study and the consent
forms were approved by institutional re-
view boards at all participating institu-
tions. The trial was funded by the
National Institutes of Health. All partici-
pantsprovidedwritteninformedconsent.
Baseline clinical and laboratory investiga-
tions were obtained in the morning after
an overnight fast as described (10).
Electrocardiogram-derived measures
of HRV
We used baseline standard 12-lead digi-
tized electrocardiograms (ECGs), re-
corded over 10 consecutive seconds with
the patient resting supine after an over-
night fast (GE MAC 1200 electrocardio-
graph system). The ECG recordings were
transferred by analog phone line to the
reading center and were analyzed and re-
viewed to determine their technical qual-
ity. Recordings that were missing (1,034)
or demonstrated poor quality (362) and
recordings from those with pacemakers
(65), atrial ﬁbrillation (108), premature
beats/other arrhythmias (542), and atrio-
ventricular conduction abnormalities (5)
were excluded from these analyses, leav-
ingacohortof8,135participantsassessed
for HRV. The following time domain
markers of cardiac autonomic tone were
computed: heart rate and the SD of nor-
mally conducted R-R intervals (SDNN).
From simultaneous lead recordings, QT
intervals were measured, and the QT in-
dex (QTI) was calculated as observed/
predicted QT duration where predicted
value was based on Bazett’s correction
(QTc  QT/R  R
1/2). Resting heart rate
reﬂects both overall autonomic function
and cardiorespiratory ﬁtness (11), SDNN
represents joint sympathetic/parasympa-
theticmodulationofheartrateinthetime
domain (11,12), QT duration represents
the time between the onset of ventricular
activation and the end of repolarization, a
process controlled in part by sympathetic
input (13,14). Impaired HRV is an easily
measured sensitive marker of CAN that
may occur early in the course of diabetes
(15).
Deﬁnitions of CAN and DPN
CAN was deﬁned by measures of HRV
and QTI. Lower HRV and higher resting
heart rate and QTI indicate poorer auto-
nomic function (11). These measures are
a reliable estimate of CAN and are recom-
mended for use in large population stud-
ies (12). DPN was documented by any
pedal amputation or a score 2o nt h e
clinical examination portion of the Mich-
igan Neuropathy Screening Instrument, a
validatedtoolforassessingDPNthateval-
uates abnormalities in foot appearance,
ankle reﬂexes, and vibration at the great
toe of both feet (16).
The following composite measures
werecomputedtodocumentthepresence
of CAN: 1) CAN1 deﬁned as the lowest
quartile of SDNN (7.815 ms) and the
highest quartile of QTI (104.32%); 2)
CAN2asthelowestquartileofSDNNand
the highest quartiles of QTI and resting
heart rate; and 3) CAN3 as the lowest
quartile of SDNN and the highest quar-
tilesofQTIandheartrate,inthepresence
of DPN. Our rationale for using these
composite prespeciﬁed deﬁnitions of
CAN was that combined abnormalities in
HRV and QT interval have demonstrated
stronger predictive value for mortality
than either abnormality alone in patients
with diabetes (13,14). The presence of
DPN was included in one of the compos-
ite measures because of prior evidence
linkingexcessmortalitytothepresenceof
DPN (6,7).
Outcome measures
The outcomes were all-cause and CVD
mortality (adjudicated by a blinded panel
usingpredeﬁnedadjudicationprocesses).
Death from CVD included deaths from
myocardial infarction, heart failure, ar-
rhythmia, invasive cardiovascular inter-
ventions, cardiovascular causes after
noncardiovascular surgery, stroke, unex-
pected death presumed to be from isch-
emic CVD occurring within 24 h after the
onset of symptoms, and death from other
vascular diseases.
Statistical analysis
We hypothesized that the increased all-
cause and CVD mortality with INT ob-
served in the ACCORD trial was due to a
higher risk of mortality with INT in the
subset of individuals with baseline CAN.
We also assessed whether CAN was re-
latedtomortalityriskindependentofgly-
cemia treatment and compared the
strength of these relationships across the
prespeciﬁed deﬁnitions of CAN.
These analyses are based on data col-
lected on participants at the time of ran-
domization and all-cause and CVD
mortalitydatasubmittedtothecoordinat-
ing center through 10 December 2007,
thecutoffdateusedbytheDataandSafety
Monitoring Board to make its recommen-
dation to stop intensive glycemia treat-
ment. Baseline characteristics were
compared between excluded and in-
cluded participants and between CAN-
positive and CAN-negative groups using

2 and two sample t tests. Analysis of all-
cause and CVD mortality was performed
with time-to-event methods according to
the intention-to-treat principle. Risk of
these outcomes was evaluated through
the use of hazard ratios (HR) and 95%
CIs. Two-sided P values were obtained
fromWald
2testsderivedfromCoxpro-
portional hazards regression analysis. For
both outcomes, we examined minimally
adjusted models stratiﬁed for treatment
allocation and history of CVD. We also ﬁt
fully adjusted models containing treat-
ment allocation, history of CVD, and the
following prespeciﬁed baseline covari-
ates: age, sex, ethnicity, diabetes dura-
tion, A1C, BMI, systolic blood pressure
(SBP) and diastolic blood pressure (DBP),
LDL cholesterol, triglycerides, urinary
microalbumin-to-creatinine ratio, and
use of thiazolidinediones (TZDs), insulin,
-blockers, ACE inhibitors/angiotensin
receptor blockers, statins, alcohol, and
cigarettes. Participants with missing co-
variates (n  235) were excluded from
fully adjusted analyses. Because results
were similar between models, only the
fully adjusted models are presented here.
We assessed the consistency of the effect
of glycemia treatment allocation on all-
cause and CVD mortality among pre-
speciﬁed subgroups using statistical tests
of interaction between treatment alloca-
tion and each subgroup within the Cox
model. Event rates are expressed as the
percentage of events per follow-up year,
taking into account censoring of fol-
low-updata,with95%PoissonCIscalcu-
lated using large sample methods. We
havealsoexaminedCANeffectsafteradd-
ing events of severe hypoglycemia requir-
ing medical assistance to the Cox
regression models as a time-dependent
covariate.
RESULTS— For the current analyses,
we included 8,135 ACCORD trial partici-
pants with complete data, including 4,050
(79%) randomly assigned to the INT arm
and 4,085 (80%) to the STD arm (supple-
Pop-Busui and Associates
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pendix at http://care.diabetesjournals.org/
cgi/content/full/dc10-0125/DC1). The
main reason for missing data was failure
ofthesitetocaptureandtransmitanelec-
tronic ECG record (n  1,034). Other
reasons for exclusion, including arrhyth-
mias (n  542), were described in the
RESEARCH DESIGN AND METHODS.
The baseline characteristics of these
participants, comparing those with (in-
cluded) and without (excluded) available
CAN measures are shown in supplemen-
tary Table A1 (available in an online ap-
pendix). This was a cohort with long
diabetes duration, elevated A1C levels,
and multiple associated CVD risk factors
as prespeciﬁed by the ACCORD trial de-
sign.Participantsexcludedfromthisanal-
ysis due to inadequate ECG data were
older (P  0.0001), were more likely to
have had a previous cardiovascular event
(P  0.0002), and had a longer diabetes
duration (P  0.045). Sex, triglyceride
levels, and -blocker use also showed
signiﬁcant differences (supplementary
Table A1).
Participants with CAN at baseline
(Table 1) consistently had higher A1C,
BMI, DBP, and triglycerides (P  0.01 in
all cases) and were more likely to use in-
sulin and to be female (P  0.01 for all
three deﬁnitions of CAN) than those
without CAN. Minority status, prior
CVD, diabetes duration, SBP, urinary al-
bumin-to-creatinine ratio, smoking his-
tory, and TZD, statin, and -blocker use
showed inconsistent differences across
the three deﬁnitions of CAN.
Association between CAN and
mortality
During a mean follow-up of 3.5 years,
there were 329 deaths from all causes in
this sample of 8,351 participants. In un-
adjusted analyses, there was a signiﬁcant
increase in all-cause mortality (HR 1.61
[1.14–2.27], P  0.007 for CAN1, 2.22
[1.45–3.39], P  0.0002 for CAN2, and
2.72[1.56–4.74],P0.0004forCAN3)
(Fig. A2, available in an online appendix)
and in CVD mortality (1.93 [1.22–3.07],
P  0.005 for CAN1, 2.55 [1.41–4.60,
P  0.002 for CAN2, and 3.39 [1.59–
7.26], P  0.0002 for CAN3) compared
with those without CAN.
Table 2 shows fully adjusted HRs
(95% CI) for all-cause and CVD mortality
for participants with CAN1, CAN2, and
CAN3 compared with participants with-
out CAN. All-cause mortality remained
signiﬁcantly higher in participants with
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allocation, CVD history, and all other co-
variateslistedin RESEARCH DESIGN AND METH-
ODS (1.55 [1.09–2.21], P  0.016 for
CAN1, 2.14 [1.37–3.37], P  0.0009 for
CAN2, and 2.07 [1.14–3.76], P  0.02
for CAN3). Similar results were observed
forCVDmortality(1.94[1.20–3.12],P
0.007 for CAN1, 2.62 [1.4–4.91], P 
0.003 for CAN2, and 2.95 [1.33–6.53],
P  0.008 for CAN3) (Table 2).
Effects of glycemia treatment and
CAN on mortality
After adjustment for covariates, the over-
all HR for all-cause mortality for INT ver-
sus STD arm in the 8,135 participants
analyzed herein was 1.17(95% CI 0.94–
1.46, P  0.17). The HR for mortality in
the INT versus STD arm for participants
with missing ECG data (1.25 [0.88–
1.78])wasnotsigniﬁcantlydifferentfrom
that of participants included in this anal-
ysis (Pinteraction  0.77), although partic-
ipants with missing ECG data were more
likely to die (1.72 vs. 1.15% per year for
includedparticipants)regardlessofglyce-
mia treatment group.
Figure1Ashowstheeventrateforall-
cause mortality by treatment group, INT
versus STD, as a function of CAN in the
analyzed cohort, using the three prespeci-
ﬁed CAN deﬁnitions. After adjustment for
all covariates, there was no signiﬁcant dif-
ference in all-cause mortality among any of
the subgroups deﬁned by the presence of
CAN1, CAN2, and CAN3 (Pheterogeneity 
0.7 for all).
The overall HR for CVD mortality
(INT versus STD) in the subgroup of in-
dividuals analyzed herein was 1.30 (95%
CI 0.93–1.82). As with all-cause mortal-
ity, in fully adjusted analyses, the HR for
thetreatmentdifferenceinCVDmortality
was not affected signiﬁcantly by CAN sta-
tus for any of the deﬁnitions examined
(Fig. 1B). We have also adjusted for the
presence of severe hypoglycemia during
the trial in the individuals with baseline
CAN. The lack of a signiﬁcant effect of
CAN on all-cause mortality in the INT
arm compared with the STD arm per-
sisted after controlling for the presence
of severe hypoglycemia in the model
(Pinteraction  0.25 for all three deﬁni-
tions of CAN).
CONCLUSIONS— These data con-
ﬁrm in one of the largest and most care-
fully characterized cohorts of patients
with type 2 diabetes that the presence of
CAN strongly predicts all-cause and CVD
mortalityindependentlyofbaselineCVD,
diabetes duration, and multiple other im-
portant CVD risk factors. However, the
increased risk of either all-cause or CVD
mortality in individuals with CAN com-
paredwiththosewithoutCANatbaseline
was similar in the INT versus the STD
glycemia treatment group. These ﬁndings
add substantial epidemiological evidence
regarding the prognostic importance of
CAN.
CAN is frequently observed in pa-
tients with diabetes. Associations be-
tween measures of CAN and mortality,
including sudden death, have been de-
scribed previously (5,17,18). In a recent
large meta-analysis, Maser et al. (5) re-
ported that the presence of CAN was as-
sociated with a greater than threefold
increase in mortality and sudden death.
Silent ischemic heart disease or cardiac
arrhythmias have both been invoked as
contributors to sudden death. In the De-
tection of Ischemia in Asymptomatic Di-
abetics (DIAD) study of 1,123 patients
with type 2 diabetes, CAN was a strong
predictor of silent ischemia and subse-
quent cardiovascular events (4).
Because CAN is associated with mul-
tiple factors including duration of diabe-
tes, severity of hyperglycemia, and the
presence of coronary artery disease, the
exact contribution of CAN to the in-
creasedmortalityriskhasbeendifﬁcultto
quantify in prior studies. The present
analysis in the ACCORD cohort provided
auniqueopportunitytoevaluateandcon-
ﬁrm the independent effect of CAN on
all-cause and CVD mortality.
Studystrengthswerethelargesample
size of high-risk participants analyzed,
the balanced sex randomization, diverse
ethnic participation, high rate of follow-
up, and rigorous CVD end point adjudi-
cation procedures. These data document
that the presence of CAN strongly pre-
dicts all-cause and CVD mortality inde-
pendently of multiple important CVD
risk factors in this high-risk cohort with
type 2 diabetes. These observations sug-
gest that documenting CAN in individu-
als with type 2 diabetes identiﬁes a subset
at higher risk for CVD events and that
CAN may explain at least in part the in-
creased risk of CVD events observed in
type 2 diabetes. Furthermore, these data
indicate that CAN should be considered
in models of CVD and mortality risk in
type 2 diabetes cohorts.
Although clinical symptoms of auto-
nomic dysfunction usually occur late in
the course of diabetes, subclinical CAN,
manifested as impaired HRV, may be de-
tected within 1 year of diagnosis in type 2
diabetesandwithin2yearsofdiagnosisin
type1diabetes(15).Traditionally,thedi-
agnosis of CAN involves a number of
tests, including the R-R response to deep
breathing, postural changes and during
Valsalva maneuver, or 24-h ECG record-
ings, which may be cumbersome to per-
form uniformly, especially in large
multicenter trials such as ACCORD. This
studydemonstratesthatusingacombina-
tion of HRV and QTI measurements de-
rived from a standard 10-s ECG can
identify subsets of patients at increased
mortality risk independently of tradi-
tional CVD risk factors. HRV and QT ab-
normalities have different origins, as
reﬂected by a weak correlation between
the two parameters demonstrated by this
study (data not shown) and by others
(13).DecreasedHRVisanearlymarkerof
cardiovascular parasympathetic dysfunc-
tion.TheQTintervalabnormalitieshavea
differentpathophysiologicalbackground,
representing the consequences of sympa-
thetic tone on cardiac depolarization and
repolarization (13). The ACCORD ﬁnd-
ings in type 2 diabetes are in line with
another recent report in patients with
Table 2—HR (95% CI) for all-cause and CVD mortality in participants with CAN compared
with participants without CAN
Measure
All-cause mortality* CVD mortality*
HR (95% CI):
CAN	/CAN P
HR (95% CI):
CAN	/CAN P
CAN1 1.55 (1.09–2.21) 0.016 1.94 (1.20–3.12) 0.007
CAN2 2.14 (1.37–3.37) 0.0009 2.62 (1.40–4.91) 0.003
CAN3 2.07 (1.14–3.76) 0.02 2.95 (1.33–6.53) 0.008
*Adjusted for treatment allocation, CVD history, and other prespeciﬁed covariates including baseline age,
sex, ethnicity, diabetes duration, A1C, BMI, SBP and DBP, LDL cholesterol, triglycerides, microalbumin-to-
creatinineratio,anduseofTZDs,insulin,-blockers,ACEinhibitors/angiotensin-receptorblockers,statins,
alcohol, and cigarettes.
Pop-Busui and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 1581Figure 1—A: Effects of CAN and glycemia intervention on all-cause mortality: HRs adjusted for treatment allocation and baseline age, sex, ethnicity,
diabetes duration, A1C, BMI, SBP and DBP, LDL cholesterol, triglycerides, microalbumin-to-creatinine ratio, CVD history, and use of TZDs, insulin,
-blockers, ACE inhibitors/angiotensin receptor blockers, statins, alcohol, and cigarettes. B: Effects of CAN and glycemia intervention on CVD mortality:
HRs adjusted for treatment allocation and baseline age, sex, ethnicity, diabetes duration, A1C, BMI, SBP and DBP, LDL cholesterol, triglycerides,
microalbumin-to-creatinine ratio, CVD history, and use of TZDs, insulin, ACE inhibitors/angiotensin-receptor blockers, -blockers, statins, alcohol, and
cigarettes. CAN1 was deﬁned as the lowest quartile of SDNN, and the highest quartile of QTI, CAN2 as the lowest quartile of SDNN, the highest quartile
of QTI, and the highest quartile of heart rate, and CAN3 as the lowest quartile of SDNN and the highest quartiles of QTI and heart rate in the presence of
DPN.
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mortality risk with combined abnormali-
ties in HRV and QT interval (13). This
ﬁnding has important implications be-
cause these measures obtained from a
standard ECG can be used as a noninva-
sive and objective method for assessing
CANinotherlargetrialsaswellasinclin-
ical practice.
Despite the signiﬁcant increase in the
mortality risk in all subgroups of partici-
pants with CAN, we did not ﬁnd that the
presence of CAN at baseline contributed
signiﬁcantly to the increased mortality
observed with the intensive versus stan-
dard treatment of glycemia in this cohort.
This ﬁnding may have practical implica-
tions for diabetes care. Control of blood
glucose is a cornerstone of diabetes man-
agementbecausemoreintensiveglycemic
control decreases the incidence and pro-
gression of diabetic microvascular (1,2)
and,insomestudies,macrovascularcom-
plications (19). The reported excess mor-
talityintheintensivearmoftheACCORD
trial (3) has led to controversy about im-
plementation of intensive glucose control
in patients with type 2 diabetes although
two other major trials, Action in Diabetes
and Vascular Disease: Preterax and Dia-
micronModiﬁedReleaseControlledEval-
uation (ADVANCE) and Veterans Affairs
Diabetes Trial (VADT), reported no in-
crease in mortality with intensive treat-
ment compared with standard treatment
in type 2 diabetes (20,21). Furthermore,
thelong-termfollow-upoftheUKPDSco-
hort reported risk reductions for myocar-
dial infarction and death from any cause
associated with intensive glucose control
(22).
One of the most feared consequences
of rigorous glycemic control is an in-
creased incidence of hypoglycemia (1,2).
Priorandmorerecentreportshaveshown
strong associations between hypoglyce-
mia and increased mortality (23,24). Hy-
poglycemia can impair hormonal and
autonomic responses to subsequent hy-
poglycemia (8), and hypoglycemia may
promote a reduced threshold for malig-
nant arrhythmias and subsequent sudden
cardiacdeath.Likewise,arecentstudyre-
ported that exposure to hypoglycemia
leads to impaired cardiovascular auto-
nomic function in healthy volunteers (9).
IntheACCORDtrial,eventhoughpartic-
ipants with severe hypoglycemia were at
higher risk of death, this risk was not ex-
plained by CAN; after adjusting for the
effects of postrandomization hypoglyce-
mia, we could not document that CAN
was an independent determinant of the
highermortalityassociatedwithintensive
glycemia treatment. Therefore, our data
imply that type 2 diabetic patients with
CAN are not necessarily at increased risk
with intensive versus standard glucose
management.
There are several limitations to our
analysis. HRV measures were limited by
the short duration of the standard ECG
recordings and by the absence of control
for respiration. The prevalence of CAN
may be higher in the excluded subset be-
cause of their older age, longer diabetes
duration, and higher prevalence of CVD.
Although the large sample of participants
analyzed and their uniform characteriza-
tion probably provides a reasonable esti-
mateofCANprevalence,itispossiblethat
we underestimated the true effect of CAN
on mortality in this cohort. There was
limited statistical power to detect an in-
teraction between subgroups deﬁned by
the presence or absence of CAN because
the study was not designed for this pur-
pose. There remains a theoretical possi-
bility that CAN was worsened by
intensive treatment during the trial and
did account for the increased mortality
with intensive treatment. We believe that
this possibility is unlikely, considering
that recent evidence showed a beneﬁcial
effect of intensive glucose treatment on
CAN in type 1 diabetes (25).
Last, because the ACCORD trial was
not designed to ascertain interactions be-
tween CAN and a rapid lowering of A1C
or/andhypoglycemiaandconsideringthe
posthocnatureofouranalysis,wecannot
drawmorespeciﬁcconclusionsregarding
the precise mechanisms involved by
which CAN increases mortality. Incom-
plete understanding of the role of CAN in
the pathogenesis of CVD and the precise
mechanisms underlying its associations
with mortality are areas deserving further
research.
Insummary,althoughCANwasasso-
ciated with increased all-cause and CVD
mortality in the ACCORD trial, these
analyses indicate that among the subset
with CAN, assignment to intensive com-
pared with standard glycemia treatment
was associated with similar mortality out-
comes. Considering the vast array of vari-
ables that could have contributed to the
increased mortality in the INT arm, it will
bedifﬁcultandperhapsimpossibletosort
out the true determinants of this out-
come.However,thepresenceofCAN,de-
ﬁned by simple, easily derived resting
ECG measures, identiﬁed a subset of type
2 diabetic patients at higher all-cause and
CVD mortality risk independent of mul-
tiple traditional CVD risk factors.
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